Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
RISPERIDONE DEPOT may leads to higher adverse events: Movement disorder ‐ any extra pyramidal symptoms compared with ORAL OLANZAPINE (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events: a. mild hypoglycaemia (episodes per participant)
1 finding from 1 review
Intervention not reported
Adverse events: a. mild hypoglycaemia (episodes per participant)
1 finding from 1 review
Adverse events (reported in the first 7 days after the procedure) · children with acute postoperative pain
1 finding from 1 review
Adverse events (reported in the first 7 days after the procedure) · children with acute postoperative pain
Ibuprofen probably leads to lower adverse events (reported in the first 7 days after the procedure) compared with morphine (moderate certainty).
1 finding from 1 review
Adverse events (reported in the first 7 days after the procedure) · children with acute postoperative pain
1 finding from 1 review
Adverse events (reported in the first 7 days after the procedure) · children with acute postoperative pain
Ibuprofen showed no clear difference in adverse events (reported in the first 7 days after the procedure) compared with placebo (low certainty).
1 finding from 1 review
Adverse effects (tooth staining and other side effects) · Children and adults with active dental caries (aged 1-50; mostly preschool/school children with primary dentition)
SDF commonly causes black staining of arrested lesions; only mild, transient adverse events were reported, with no major adverse events (ungraded).
1 finding from 1 review
Local adverse events: skin thinning; end of treatment (2‐5 weeks) · children and adults, most with moderate to severe eczema
1 finding from 1 review
Local adverse events: skin thinning; end of treatment (2‐5 weeks) · children and adults with mild to severe eczema
Moderate‐potency may leads to lower local adverse events: skin thinning; end of treatment (2‐5 weeks) compared with mild‐potency topical corticosteroid (low certainty).
1 finding from 1 review
Adverse events: participants incurring one or more adverse events · participants undergoing rehabilitation following surgery for flexor tendon injuries of the handa
1 finding from 1 review
Adverse events: participants incurring one or more adverse events · participants undergoing rehabilitation following surgery for flexor tendon injuries of the handa
1 finding from 1 review
Adverse events: participants incurring one or more adverse events · participants undergoing rehabilitation following surgery for flexor tendon injuries of the handa
It is very uncertain whether early active flexion plus controlled passive exercise regimen changes adverse events: participants incurring one or more adverse events compared with early controlled passive exercise regimen (very low certainty).
1 finding from 1 review
Specific adverse events: gastrointestinal perforations or fistulae · women with persistent, recurrent, or metastatic cervical cancer
Bevacizumab plus chemotherapy probably leads to higher specificadverse events: gastrointestinal perforations or fistulae compared with chemotherapy (moderate certainty).
1 finding from 1 review
Side effects or other adverse events · adults with antisocial personality disorder
1 finding from 1 review
Number experiencing adverse effects · children (12 or over) and adults with cystic fibrosis and lung infection
It is very uncertain whether summary of findings: monoclonal antibody KB001‐A changes adverse events number of participants experiencing adverse events compared with placebo (very low certainty).
1 finding from 1 review
Discontinued treatment due to adverse events measured at a median · men with metastatic, hormone‐sensitive prostate cancer
Abiraterone + ADT probably leads to higher discontinued treatment due to adverse events measured at a median compared with ADT alone (moderate certainty).
1 finding from 1 review
Serious adverse events (leflunomide) assessed by number of events · psoriatic arthritis
1 finding from 1 review
Serious adverse events (irrespective of attribution to treatment)
Pembrolizumab may leads to lower serious adverse events (irrespective of attribution to treatment) compared with chemotherapy (low certainty).
1 finding from 1 review
All‐cause mortality or other serous adverse events of the newborn
1 finding from 1 review